Abstract:Current therapies for pulmonary arterial hypertension (PAH) mainly focus on the abnormalities in the prostacyclin, nitric oxide and endothelin pathways. These drugs fail to markedly improve morbidity and mortality, and thereby identification of novel druggable targets is still critically needed for effective treatment of PAH in patients. Our previous studies have identified the prerequisite role of HIF-2α activation in mediating obliterative pulmonary vascular remodeling and development of severe PAH (Dai, Circulation 2016), suggesting that targeting HIF-2α represents a novel strategy for the treatment of severe PAH. Our recent data showed that endothelial HIF-2α and its downstream targets are activated in IPAH patients. Pharmacological inhibition of HIF-2α with a novel HIF-2α-selective inhibitor markedly reduced right ventricle systolic pressure (RVSP) and RV hypertrophy and prevented right heart failure as well as inhibited pulmonary vascular remodeling in mice with Tie2Cre-mediated deletion of Egln1, which is the first mouse model of severe PAH recapitulating many of the characteristic features of clinical PAH including vascular occlusion and plexiform-like lesions as well as right heart failure. This compound also inhibited RVSP and RV hypertrophy and thereby PAH in rats challenged with Sugen 5416/Hypoxia. Together, these studies for the first time demonstrate that targeting HIF-2α is a promising therapeutic strategy for effective treatment of PAH and thereby promoting survival. Support or Funding Information NIH grants R01HL123957, R01HL125350, R01HL133951, and P01HL077806 (Project 3) to Y.Y.Z, AHA postdoctoral fellowship grant 15POST25700124 to Z.D. Activation of endothelial HIF-2a and its downstream targets in IPAH patients. (A) QRT-PCR analysis demonstrating increased of HIF-2a and its target genes in the lung of IPAH patients compared to that of normal donor. (B) Immunofluorescent staining showing increase of endothelial HIF-2a expression in the luminal side of pulmonary arterial of IPAH. V, vessels. *, p<0.05. HIF-2a inhibitors suppressed HIF-2a activation. (A) Luciferase assay showing that HIF-2a antagonist-2 (H2A) and HIF-2a translation inhibitor compound 76 (C76) inhibited DMOG (1mM) induced HIF activation in HLMECs. (B) Luciferase assay demonstrating that both H2A and C76 suppressed PHD2 silencing induced HIF activation in HLMECs. (C) QRT-PCR analysis showed that C76 selectively inhibited HIF-2a targets CXCL12, PDGFB, GREM1 but not CXCR4. *, P<0.05. ***, ###, P<0.001. Pharmacological inhibition of HIF-2a in severe PAH mouse model. (A) Strategy of C76 treatment in Egln1Tie2 mice. (B) Dramatic decrease of RVSP in C76 treated Egln1Tie2 mice. (C) Marked inhibition of RV hypertrophy in C76 treated Egln1Tie2 mice. (D)Echocardiography showing normalization of PA function by C76 treatment. (E) (F) Echocardiography measurement demonstrating increase of PA AT and PA AT/ET ratio in C76 treated Egln1Tie2 mice. **P<0.01; ***P<0.001. Normalization of pulmonary vasculature pathology and molecules by HIF-2a inhibition. (A) Representative Russel Movat pentachrome staining showing reduction of neointima, decrease of wall thickness and adventitia by in C76 treated Egln1Tie2 mice. (B) (C) Anti-a-SMA staining demonstrating decrease of distal pulmonary arterial muscularization in C76 treated Egln1Tie2 mice. (D) QRT-PCR analysis demonstrating normalization of PH-causing genes by C76 treatment in Egln1Tie2 mice. HIF-2a inhibitor inhibited RV hypertrophy and prevented RV failure. (A) (B) Echocardiography showing decrease of RV wall thickness in C76 treated Egln1Tie2 mice. (C) (D) Representative WGA staining showing that C76 decreased cardiomyocyte hypertrophy in vivo. (E) Trichrome staining showing reduction of RV fibrosis by C76. (F) Echocardiography showing restoration of RV fraction area change in C76 treated Egln1Tie2 mice. (G) Reduced mortality by C76 treatment in Egln1Tie2 mice.

The Effect of HIF Inhibition on the Phenotype of Fibroblasts in Human and Bovine Pulmonary Hypertension

Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1

Hif2 Alpha is Required for the Development of Pulmonary Vascular Fibrosis Associated with Pulmonary Arterial Hypertension

Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor.

Mutual inhibitory mechanisms between PPARγ and Hif-1α: implication in pulmonary hypertension.

Microenvironmental regulation of T-cells in pulmonary hypertension

Hypoxia-inducible factor signaling in pulmonary hypertension.

Mutual Promotion of FGF21 and PPARγ Attenuates Hypoxia-Induced Pulmonary Hypertension

Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension.

Pathobiological characterization of pulmonary hypertension associated with heart failure with preserved ejection fraction

Fibroblasts in Pulmonary Hypertension: Roles and Molecular Mechanisms

Abstract 9804: Overexpression of Pericyte Hif2a Exacerbates Hypoxia Induced Pulmonary Hypertension and Right Ventricular Hypertrophy

Multimodal Imaging Reveals that Sustained Inhibition of HIF-Prolyl Hydroxylases Induces Opposing Effects on Right and Left Ventricular Function in Healthy Rats

Selective Targeting HIF‐2α for Treatment of Pulmonary Arterial Hypertension

Loss of Prolyl Hydroxylase 1 and 2 in SM22α-Expressing Cells Prevents Hypoxia-Induced Pulmonary Hypertension.

Reversal of Pulmonary Hypertension in a Human-Like Model: Therapeutic Targeting of Endothelial DHFR

Hypoxic Mast Cells Accelerate the Proliferation, Collagen Accumulation and Phenotypic Alteration of Human Lung Fibroblasts

Effect of Hypoxia on Fibroblast Proliferation in Idiopathic Pulmonary Fibrosis

Function of pulmonary arterial fibroblasts in hypoxic pulmonary hypertension

Role of Hypoxia-Inducible Factors in Regulating Right Ventricular Function and Remodeling during Chronic Hypoxia-induced Pulmonary Hypertension

Hypoxia Promotes Pulmonary Vascular Remodeling Via HIF-1α to Regulate Mitochondrial Dynamics